Earnings
Home›Earnings›Analyst Ratings›Michael Burry boosts Zoetis stake amid Librela and Sol…
Michael Burry boosts Zoetis stake amid Librela and Solensia scrutiny
Zoetis is launching new osteoarthritis therapies in Canada and the EU, while safety concerns have weighed on sales of Librela and Solensia ahead of its second-quarter earnings.
Zoetis faces headwinds in companion animal products as competition intensifies, and its brands Convenia and Cerenia are facing greater pressure from generic offerings, according to Yahoo Finance. The company is also dealing with slower sales from Librela, a monoclonal antibody for osteoarthritis pain in pets, amid safety concerns raised around its use, with Solensia also coming under fire.
Yahoo Finance notes that Librela has received support from the Veterinary Medicines Directorate in the U.K., adding some regulatory balance to the debate. In parallel, Zoetis has launched Lenivia, an injectable osteoarthritis therapy for dogs, and Portela, its feline counterpart, in Canada and the EU, aiming to offset some of the pressure tied to products under scrutiny.
The outlet also highlights Zoetis has a pipeline with 12 candidates across areas of unmet medical need, including chronic kidney disease, oncology, cardiology, anxiety, and obesity. With second-quarter earnings approaching, the article says Michael Burry increased his position in Zoetis, framing it as a long-term bet on animal healthcare rather than short-term gains tied to other high-profile themes.
Zoetis is a global animal health company with operations spanning research, production, and commercial support for livestock and companion animals. Yahoo Finance describes the company as headquartered in Parsippany, New Jersey, and gives its market capitalization as $32.4 billion.